Table 2.
In-hospital clinical outcomes and treatments for adults admitted to hospital with covid-19 during the omicron period (26 December 2021 to 15 June 2022), by vaccination status. Values are numbers (percentages) of total
| Outcome | Total | Unvaccinated | Completed primary series | Primary series+one booster dose | Primary series+two booster doses |
|---|---|---|---|---|---|
| Status at 28 days after admission: | |||||
| Remained in hospital | 152/2153 (7.1) | 71/807 (8.8) | 64/862 (7.4) | 16/459 (3.5) | 1/25 (4.0) |
| Discharged | 1848/2153 (85.8) | 661/807 (81.9) | 745/862 (86.4) | 419/459 (91.3) | 23/25 (92.0) |
| Died | 153/2153 (7.1) | 75/807 (9.3) | 53/862 (6.1) | 24/459 (5.2) | 1/25 (4.0) |
| Admitted to intensive care unit | 547/2150 (25.4) | 250/806 (31.0) | 202/860 (23.5) | 91/459 (19.8) | 4/25 (16.0) |
| Any oxygen support: | 1509/2153 (70.1) | 600/807 (74.3) | 586/862 (68.0) | 305/459 (66.4) | 18/25 (72.0) |
| HFNC | 385/2153 (17.9) | 196/807 (24.3) | 145/862 (16.8) | 43/459 (9.4) | 1/25 (4.0) |
| NIPPV | 232/2153 (10.8) | 108/807 (13.4) | 89/862 (10.3) | 32/459 (7.0) | 3/25 (12.0) |
| IMV | 268/2153 (12.4) | 142/807 (17.6) | 87/862 (10.1) | 36/459 (7.8) | 3/25 (12.0) |
| ECMO | 18/2153 (0.8) | 15/807 (1.9) | 3/862 (0.3) | 0/459 (0) | 0/25 (0) |
| Vasopressors | 276/2153 (12.8) | 137/807 (17.0) | 97/862 (11.3) | 40/459 (8.7) | 2/25 (8.0) |
| New renal replacement therapy | 61/2153 (2.8) | 32/807 (4.0) | 24/862 (2.8) | 5/459 (1.1) | 0/25 (0) |
| Venous thromboembolic event* | 130/2153 (6.0) | 71/807 (8.8) | 44/862 (5.1) | 15/459 (3.3) | 0/25 (0) |
| Stroke | 26/2153 (1.2) | 14/807 (1.7) | 8/862 (0.9) | 4/459 (0.9) | 0/25 (0) |
| Myocardial infarction | 42/2153 (2.0) | 18/807 (2.2) | 14/862 (1.6) | 10/459 (2.2) | 0/25 (0) |
| Composite of death or IMV | 338/2153 (15.7) | 164/807 (20.3) | 121/862 (14.0) | 50/459 (10.9) | 3/25 (12.0) |
| Treatment for severe covid-19: | 1203/2012 (59.8) | 496/733 (67.7) | 474/807 (58.7) | 223/447 (49.9) | 10/25 (40.0) |
| Corticosteroids | 1199/2012 (59.6) | 495/733 (67.5) | 472/807 (58.5) | 222/447 (49.7) | 10/25 (40.0) |
| Tocilizumab | 53/2012 (2.6) | 29/733 (4.0) | 19/807 (2.4) | 5/447 (1.1) | 0/25 (0) |
| Baricitinib | 96/2012 (4.8) | 67/733 (9.1) | 28/807 (3.5) | 1/447 (0) | 0/25 (0) |
| Anti-SARS-CoV-2 monoclonal antibodies | 68/2012 (3.4) | 19/733 (2.6) | 36/807 (4.5) | 12/447 (2.7) | 1/25 (4.0) |
ECMO=extracorporeal membrane oxygenation; HFNC=high flow nasal cannula; IMV=invasive mechanical ventilation; NIPPV=nasal intermittent positive pressure ventilation.
*
Deep vein thrombosis or pulmonary embolism, or both.